Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

NCT ID: NCT06080074

Last Updated: 2026-01-29

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-15
• Study Completion Date: 2029-09-30

Brief Summary

There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to:

1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 days of support in children with severe heart failure with the goal to support its FDA clearance in children.

2. To evaluate heparin versus bivalirudin as the primary blood thinner (anticoagulant) in a randomized trial of children supported with the Cardiohelp ECMO System with the goal to plan a phase III (pivotal) randomized clinical trial

The main questions the Cardiohelp single-arm trial seeks to answer are:

• What is the safety and effectiveness of the Cardiohelp device for pediatric ECMO?
• Should the Cardiohelp device be FDA-cleared for children based on the results of the study?
• What are the optimal performance specifications of the Cardiohelp device in children?

The main questions the blood thinner randomized trial seeks to answer are:

• Which blood thinner is more promising (i.e., more effective and safer) in children on the Cardiohelp device?
• How should a pivotal trial of heparin vs. bivalirudin be designed so it is the most informative and efficient to determine the best blood thinner?

Children who are receiving the Cardiohelp device will be approached and consented to participate if interested. For the Cardiohelp device trial, participants will undergo a standardized data collection to estimate survival to 30 days and the prevalence of serious adverse events like stroke, bleeding, and hemolysis. For the blood thinner randomized trial, participants will be randomized 1:1 to blood thinner strategy to determine which blood thinner has the fewest bleeding and clotting complications.

For the Cardiohelp single-arm trial, participant outcomes will be compared to performance goals (PG) derived from the ECMO literature. For the blood thinner randomized trial, the amount of bleeding and clotting will be measured.

The study is funded by an R01 grant from the FDA's Office of Orphan Product Development (OOPD).

Detailed Description

This is a multicenter clinical trial to evaluate the safety and effectiveness of the Cardiohelp System for up to 30 days of support in children with severe cardiac failure. The trial includes a secondary randomized study comparing heparin versus bivalirudin anticoagulation according to standard treatment protocols.

Despite more than 50 years of ECMO use that carries up to 50% mortality, no standalone ECMO device has ever received FDA clearance for pediatric ECMO. All ECMO use in children is off-label, which may contribute to substantial mortality and complications, as well as wide center-to-center variation in ECMO practices that lacks an evidence base. Additionally, while two anticoagulants (heparin and bivalirudin) are commonly used in ECMO circuits, the optimal choice remains unknown-specifically, which anticoagulant is associated with the fewest circuit clots and least bleeding.

This study, funded by an R01 clinical trials Orphan Grant from the FDA, seeks to change the current status quo. By collecting systematic safety and effectiveness data on the Cardiohelp Device, we aim to determine whether it is safe and effective enough to become the first standalone ECMO device to receive FDA clearance for up to 30 days of support in children. The FDA clearance decision will be based on how the Cardiohelp performs relative to several key performance benchmarks drawn from the published ECMO literature, which the FDA has jointly agreed upon. These benchmarks include overall survival without severe stroke, degree of hemolysis (red blood cell breakdown), frequency of circuit change due to thrombus or device malfunction, stroke rate, and kidney injury rate.

For the anticoagulant randomized trial, we will collect systematic data on clotting and bleeding complications associated with each anticoagulant. As a Phase II study, the goal is not to reach a final answer, but to design a Phase III (pivotal) trial that is as informative and efficient as possible for addressing this critical question in the field of ECMO.

Tertiary goals of the study are: (1) to determine the optimal performance range (i.e., device specifications) for the Cardiohelp device in children to inform an eventual FDA label and Instructions for Use (IFU); and (2) to provide the FDA with a predicate device to support FDA clearance of other ECMO systems under 510(k) regulation, as no predicate devices currently exist to support such regulatory comparisons.

Conditions

Heart Failure; Cardiogenic Shock; Congenital Heart Disease; Cardiomyopathies

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cardiohelp device managed according to a standardized guideline using heparin anticoagulation

Participants receiving the Cardiohelp device for severe heart failure will be managed according to a standardized treatment guideline (equipment, monitoring, etc.) where heparin is the primary blood thinner to estimate the safety and effectiveness of the device and blood thinner strategy for up to 30 days of support.

Group Type: EXPERIMENTAL

Cardiohelp device (VA-ECMO)

Intervention Type: DEVICE

The Cardiohelp system is a compact cardiopulmonary support system used off-label for ECMO for patients with cardiac and/or respiratory failure. It is currently FDA-cleared for \<6 hours of support for cardiopulmonary bypass.

Heparin

Intervention Type: DRUG

Blood thinner that works by inactivating factor Xa that is administered as a continuous intravenous infusion.

Cardiohelp device managed according to a standardized guideline using bivalirudin anticoagulation

Participants receiving the Cardiohelp device for severe heart failure will be managed according to a standardized treatment guideline (equipment, monitoring, etc.) where bivalirudin is the primary blood thinner to estimate the safety and effectiveness of the device and blood thinner strategy for up to 30 days of support.

Group Type: EXPERIMENTAL

Cardiohelp device (VA-ECMO)

Intervention Type: DEVICE

The Cardiohelp system is a compact cardiopulmonary support system used off-label for ECMO for patients with cardiac and/or respiratory failure. It is currently FDA-cleared for \<6 hours of support for cardiopulmonary bypass.

Bivalirudin

Intervention Type: DRUG

Blood thinner that works by inhibiting thrombin directly that is administered as a continuous intravenous infusion.

Interventions

Cardiohelp device (VA-ECMO)

The Cardiohelp system is a compact cardiopulmonary support system used off-label for ECMO for patients with cardiac and/or respiratory failure. It is currently FDA-cleared for \<6 hours of support for cardiopulmonary bypass.

Intervention Type: DEVICE

Heparin

Blood thinner that works by inactivating factor Xa that is administered as a continuous intravenous infusion.

Intervention Type: DRUG

Bivalirudin

Blood thinner that works by inhibiting thrombin directly that is administered as a continuous intravenous infusion.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age 0 to 16 years of age (i.e., <17 years)

2. Body weight 3 to 80 kilograms

3. VA-ECMO use for primary cardiac failure using the Cardiohelp system.

4. First ECMO run during the current hospitalization

Exclusion Criteria

1. Gestationally-corrected age <37 weeks

2. Bleeding or coagulopathy that is a contraindication to anticoagulation

3. Irreversible renal, hepatic or lung failure

4. Stroke or uncertain neurological status within the past 30 days

5. Severely malnourished

6. Use of an ECMO system other than the Cardiohelp

7. VV-ECMO or ECMO for primary respiratory failure

8. Goals of patient to focus on comfort measures only.

9. Failure to separate from cardiopulmonary bypass

10. Allergy or contraindication to receiving UFH or bivalirudin as a primary anticoagulant on ECMO.

11. Patients who are pregnant or breastfeeding.

12. Unable to undergo randomization within 30 hours following ECMO cannulation (randomized cohort only)

• Minimum Eligible Age: 0 Years
• Maximum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boston Children's Hospital

OTHER

Sponsor Role: collaborator

Duke University

OTHER

Sponsor Role: collaborator

FDA Office of Orphan Products Development

FED

Sponsor Role: collaborator

Stanford University

OTHER

Sponsor Role: lead

Responsible Party

Christopher Almond

Professor of Pediatrics

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Lynn Sleeper, ScD

Role: PRINCIPAL_INVESTIGATOR

Boston Children's Hospital

Caroline Ozment, MD

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Lucile Packard Children's Hospital

Palo Alto, California, United States

Site Status: RECRUITING

Cuimc/Nyph

New York, New York, United States

Site Status: RECRUITING

Duke University Hospital

Durham, North Carolina, United States

Site Status: RECRUITING

Children's Health Dallas

Dallas, Texas, United States

Site Status: RECRUITING

Seattle Children's Hospital

Seattle, Washington, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Christopher SD Almond, MD, MPH

Role: CONTACT

calmond@stanford.edu

6507237913

Selena Gonzales, MPH

Role: CONTACT

selena.gonzales@stanford.edu

650-723-7913

Facility Contacts

Kate Ryan, MD

Role: primary

kateryan@stanford.edu

650-724-5554

Eva Cheung, MD

Role: primary

ec2335@cumc.columbia.edu

(212) 305-8458

Caroline Ozment, MD

Role: primary

caroline.ozment@duke.edu

Sirine Baltagi, MD

Role: primary

Sirine.Baltagi@UTSouthwestern.edu

Michael McMullan, MD

Role: primary

michael.mcmullan@seattlechildrens.org

206-987-2015

Other Identifiers

72467

Identifier Type: -

Identifier Source: org_study_id